Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.

We retrospectively analyzed 38 patients with AML who received azacitidine (AZA) to treat disease relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients with objective response (OR) ( = 20) after AZA had significantly higher 2-year overall survival (OS) (45.0% vs 5.6%;  = 0.004) than progressive disease. The 2-year OS was significantly higher in the retransplant group ( = 23) than in the nonretransplant group ( = 15) (34.8% vs 13.3%;  = 0.034). We analyzed 167 patients who underwent the second allo-HSCT to clarify the impact of pretransplant AZA after the second allo-HSCT. Patients in the AZA group ( = 21) had significantly higher 2-year disease-free survival (DFS) (32.7% vs 14.5%;  = 0.012) and OS (38.1% vs 17.5%;  = 0.044) than those in the SOC group ( = 146). Our data demonstrate that AZA is an effective and well-tolerated bridging therapy to the second allo-HSCT.